Patient participants had received a variety of cancer care treatments including chemo (n = 16, 55%), surgery (n = 15, 52%), radiation (n = 14, 48%), immunotherapy (n = 7, 24%), palliative care (n = 7, 24%), stem cell/bone marrow transplant (n = 1, 3%), and other treatments (n = 6, 21%) including targeted therapy, Arimidex, lymphedema treatments, aromatase inhibitor, and clinical trials. This evidence concerns the gene CYP19A1 and lymphedema.